(NASDAQ: REGN) Regeneron Pharmaceuticals's forecast annual revenue growth rate of 4.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Regeneron Pharmaceuticals's revenue in 2025 is $14,085,700,000.On average, 7 Wall Street analysts forecast REGN's revenue for 2025 to be $1,470,575,145,952, with the lowest REGN revenue forecast at $1,385,737,153,995, and the highest REGN revenue forecast at $1,520,262,163,257. On average, 7 Wall Street analysts forecast REGN's revenue for 2026 to be $1,572,722,706,215, with the lowest REGN revenue forecast at $1,484,849,480,241, and the highest REGN revenue forecast at $1,691,851,727,639.
In 2027, REGN is forecast to generate $1,751,827,101,050 in revenue, with the lowest revenue forecast at $1,593,851,446,012 and the highest revenue forecast at $1,852,064,967,602.